Multidrug-resistant tuberculosis.
Journal
Nature reviews. Disease primers
ISSN: 2056-676X
Titre abrégé: Nat Rev Dis Primers
Pays: England
ID NLM: 101672103
Informations de publication
Date de publication:
24 Mar 2024
24 Mar 2024
Historique:
accepted:
16
02
2024
medline:
26
3
2024
pubmed:
25
3
2024
entrez:
25
3
2024
Statut:
epublish
Résumé
Tuberculosis (TB) remains the foremost cause of death by an infectious disease globally. Multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB; resistance to rifampicin and isoniazid, or rifampicin alone) is a burgeoning public health challenge in several parts of the world, and especially Eastern Europe, Russia, Asia and sub-Saharan Africa. Pre-extensively drug-resistant TB (pre-XDR-TB) refers to MDR/RR-TB that is also resistant to a fluoroquinolone, and extensively drug-resistant TB (XDR-TB) isolates are additionally resistant to other key drugs such as bedaquiline and/or linezolid. Collectively, these subgroups are referred to as drug-resistant TB (DR-TB). All forms of DR-TB can be as transmissible as rifampicin-susceptible TB; however, it is more difficult to diagnose, is associated with higher mortality and morbidity, and higher rates of post-TB lung damage. The various forms of DR-TB often consume >50% of national TB budgets despite comprising <5-10% of the total TB case-load. The past decade has seen a dramatic change in the DR-TB treatment landscape with the introduction of new diagnostics and therapeutic agents. However, there is limited guidance on understanding and managing various aspects of this complex entity, including the pathogenesis, transmission, diagnosis, management and prevention of MDR-TB and XDR-TB, especially at the primary care physician level.
Identifiants
pubmed: 38523140
doi: 10.1038/s41572-024-00504-2
pii: 10.1038/s41572-024-00504-2
doi:
Substances chimiques
Antitubercular Agents
0
Rifampin
VJT6J7R4TR
Isoniazid
V83O1VOZ8L
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
22Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© 2024. Springer Nature Limited.
Références
WHO. Global Tuberculosis Report 2023. World Health Organization https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023 (2023).
The Economist Intelligence Unit. It’s time to end drug-resistant tuberculosis. The Economist https://www.eiu.com/graphics/marketing/pdf/its-time-to-end-drug-resistant-tuberculosis-full-report.pdf (2019).
Paulson, T. Epidemiology: a mortal foe. Nature 502, S2–S3 (2013).
pubmed: 24108078
doi: 10.1038/502S2a
WHO. WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment - Drug-Resistant Tuberculosis Treatment, 2022 Update. World Health Organization https://www.who.int/publications/i/item/9789240063129 (2022).
WHO. Meeting Report of the WHO Expert Consultation on Drug-Resistant Tuberculosis Treatment Outcome Definitions. World Health Organization https://www.who.int/publications/i/item/9789240022195 (2021).
WHO Consolidated Guidelines on Drug-resistant Tuberculosis Treatment (WHO, 2019).
WHO. Global Tuberculosis Report 2022. World Health Organization https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022 (2022).
O’Neill, J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. AMR https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf (2016).
Gunther, G. et al. Treatment outcomes in multidrug-resistant tuberculosis. N. Engl. J. Med. 375, 1103–1105 (2016).
pubmed: 27626539
doi: 10.1056/NEJMc1603274
Gunther, G. et al. Availability and costs of medicines for the treatment of tuberculosis in Europe. Clin. Microbiol. Infect. 29, 77–84 (2023).
pubmed: 35961488
doi: 10.1016/j.cmi.2022.07.026
WHO. Ten Threats to Global Health in 2019. World Health Organization https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019 (2019).
WHO. Global Research Agenda for Antimicrobial Resistance in Human Health. World Health Organization https://www.who.int/publications/m/item/global-research-agenda-for-antimicrobial-resistance-in-human-health#:~:Text=It%20aims%20to%20guide%20policy,and%2Dmiddle%2Dincome%20countries (2023).
Dheda, K. et al. Drug-penetration gradients associated with acquired drug resistance in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 198, 1208–1219 (2018). Comprehensive study outlining the differential penetration of drugs into TB cavities and its association with resistance amplification.
pubmed: 29877726
pmcid: 6221573
doi: 10.1164/rccm.201711-2333OC
WHO. WHO TB country, regional and global profiles. World Health Organization https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&lan=%22EN%22&entity_type=%22country%22&iso2=%22AF%22 (2022).
Dheda, K. et al. The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. Lancet Respir. Med. 10, 603–622 (2022).
pubmed: 35338841
pmcid: 8942481
doi: 10.1016/S2213-2600(22)00092-3
Bykov, I. et al. Factors contributing to the high prevalence of multidrug-resistance/rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk Krai region of Russia. BMC Infect. Dis. 22, 612 (2022).
pubmed: 35831812
pmcid: 9281178
doi: 10.1186/s12879-022-07598-7
Faustini, A., Hall, A. J. & Perucci, C. A. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 61, 158–163 (2006).
pubmed: 16254056
doi: 10.1136/thx.2005.045963
Jeong, H. E. et al. Socioeconomic disparities and multidrug-resistant tuberculosis in South Korea: focus on immigrants and income levels. J. Microbiol. Immunol. Infect. 56, 424–428 (2023).
pubmed: 36115791
doi: 10.1016/j.jmii.2022.08.014
Feng, M. et al. Risk factors of multidrug-resistant tuberculosis in China: a meta-analysis. Public Health Nurs. 36, 257–269 (2019).
pubmed: 30680796
doi: 10.1111/phn.12582
Wingfield, T., Tovar, M. A., Datta, S., Saunders, M. J. & Evans, C. A. Addressing social determinants to end tuberculosis. Lancet 391, 1129–1132 (2018).
pubmed: 29595481
pmcid: 7611140
doi: 10.1016/S0140-6736(18)30484-7
Janssens, J. P. & Rieder, H. L. An ecological analysis of incidence of tuberculosis and ‘per capita′ gross domestic product. Eur. Respir. J. 32, 1415 (2008).
pubmed: 18978146
doi: 10.1183/09031936.00078708
Lienhardt, C. et al. Global tuberculosis control: lessons learnt and future prospects. Nat. Rev. Microbiol. 10, 407–416 (2012).
pubmed: 22580364
doi: 10.1038/nrmicro2797
Oxlade, O. & Murray, M. Tuberculosis and poverty: why are the poor at greater risk in India? PLoS ONE 7, e47533 (2012).
pubmed: 23185241
pmcid: 3501509
doi: 10.1371/journal.pone.0047533
Bhargava, A., Bhargava, M., Beneditti, A. & Kurpad, A. Attributable is preventable: corrected and revised estimates of population attributable fraction of TB related to undernutrition in 30 high TB burden countries. J. Clin. Tuberc. Other Mycobact. Dis. 27, 100309 (2022).
pubmed: 35308808
pmcid: 8924683
doi: 10.1016/j.jctube.2022.100309
Sultana, Z. Z. et al. HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis. BMC Infect. Dis. 21, 51 (2021).
pubmed: 33430786
pmcid: 7802168
doi: 10.1186/s12879-020-05749-2
Bastard, M. et al. Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: multicenter cohort study. PLoS ONE 13, e0193491 (2018).
pubmed: 29518098
pmcid: 5843270
doi: 10.1371/journal.pone.0193491
Ong, K. L. et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203–234 (2023).
doi: 10.1016/S0140-6736(23)01301-6
Tegegne, B. S., Mengesha, M. M., Teferra, A. A., Awoke, M. A. & Habtewold, T. D. Association between diabetes mellitus and multi-drug-resistant tuberculosis: evidence from a systematic review and meta-analysis. Syst. Rev. 7, 161 (2018).
pubmed: 30322409
pmcid: 6190557
doi: 10.1186/s13643-018-0828-0
Xu, G., Hu, X., Lian, Y. & Li, X. Diabetes mellitus affects the treatment outcomes of drug-resistant tuberculosis: a systematic review and meta-analysis. BMC Infect. Dis. 23, 813 (2023).
pubmed: 37986146
pmcid: 10662654
doi: 10.1186/s12879-023-08765-0
Du, D. H. et al. The effect of M. tuberculosis lineage on clinical phenotype. Preprint at medRxiv https://doi.org/10.1101/2023.03.14.23287284 (2023).
Marx, F. M. et al. The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. Clin. Infect. Dis. 58, 1676–1683 (2014).
pubmed: 24647020
doi: 10.1093/cid/ciu186
Becerra, M. C. et al. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ 367, l5894 (2019).
pubmed: 31649017
pmcid: 6812583
doi: 10.1136/bmj.l5894
Theron, G. et al. Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis. Nat. Med. 26, 1435–1443 (2020). Work indicating that DR-TB strains were as infectious as DS-TB strains, and that infectiousness was not associated with M. tuberculosis genetic variants (suggesting that epigenetic factors or host–pathogen interactions are likely important in the pathogenesis of resistance amplification).
pubmed: 32601338
pmcid: 8353872
doi: 10.1038/s41591-020-0940-2
Shah, N. S. et al. Transmission of extensively drug-resistant tuberculosis in South Africa. N. Engl. J. Med. 376, 243–253 (2017).
pubmed: 28099825
pmcid: 5330208
doi: 10.1056/NEJMoa1604544
Loiseau, C. et al. The relative transmission fitness of multidrug-resistant Mycobacterium tuberculosis in a drug resistance hotspot. Nat. Commun. 14, 1988 (2023).
pubmed: 37031225
pmcid: 10082831
doi: 10.1038/s41467-023-37719-y
Bateson, A. et al. Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid. J. Antimicrob. Chemother. 77, 1685–1693 (2022).
pubmed: 35260883
pmcid: 9155602
doi: 10.1093/jac/dkac070
Gómez-González, P. J. et al. Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid. Sci. Rep. 11, 19431 (2021).
pubmed: 34593898
pmcid: 8484543
doi: 10.1038/s41598-021-98862-4
Brown, T. S. et al. Evolution and emergence of multidrug-resistant Mycobacterium tuberculosis in Chisinau, Moldova. Microb. Genom. 7, 000620 (2021).
pubmed: 34431762
pmcid: 8549355
Dheda, K. et al. The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respir. Med. 7, 820–826 (2019).
pubmed: 31486393
doi: 10.1016/S2213-2600(19)30263-2
Adam, D. C. et al. Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong. Nat. Med. 26, 1714–1719 (2020).
pubmed: 32943787
doi: 10.1038/s41591-020-1092-0
Perdigão, J. et al. Using genomics to understand the origin and dispersion of multidrug and extensively drug resistant tuberculosis in Portugal. Sci. Rep. 10, 2600 (2020).
pubmed: 32054988
pmcid: 7018963
doi: 10.1038/s41598-020-59558-3
Salvato, R. S. et al. Genomic-based surveillance reveals high ongoing transmission of multi-drug-resistant Mycobacterium tuberculosis in Southern Brazil. Int. J. Antimicrob. Agents 58, 106401 (2021).
pubmed: 34289403
doi: 10.1016/j.ijantimicag.2021.106401
Sara, C. A. et al. Extensively drug-resistant tuberculosis in South Africa: genomic evidence supporting transmission in communities. ERJ 52, 1800246 (2018).
doi: 10.1183/13993003.00246-2018
Srilohasin, P. et al. Genomic evidence supporting the clonal expansion of extensively drug-resistant tuberculosis bacteria belonging to a rare proto-Beijing genotype. Emerg. Microbes Infect. 9, 2632–2641 (2020).
pubmed: 33205698
pmcid: 7738298
doi: 10.1080/22221751.2020.1852891
Vaziri, F. et al. Genetic diversity of multi- and extensively drug-resistant Mycobacterium tuberculosis isolates in the capital of iran, revealed by whole-genome sequencing. J. Clin. Microbiol. 57, e01477–e01518 (2019).
pubmed: 30404943
pmcid: 6322472
doi: 10.1128/JCM.01477-18
McMurray, D. N. in Tuberculosis: Pathogenesis, Protection, and Control (ed. Bloom B. R.) 135–147 (ASM, 1994).
Jones-López, E. C. et al. Cough aerosols of Mycobacterium tuberculosis predict new infection. A household contact study. Am. J. Respir. Crit. Care Med. 187, 1007–1015 (2013).
pubmed: 23306539
pmcid: 3707366
doi: 10.1164/rccm.201208-1422OC
Cattamanchi, A. et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J. Acquir. Immune Defic. Syndr. 56, 230–238 (2011).
pubmed: 21239993
pmcid: 3383328
doi: 10.1097/QAI.0b013e31820b07ab
Rangaka, M. X. et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect. Dis. 12, 45–55 (2012).
pubmed: 21846592
doi: 10.1016/S1473-3099(11)70210-9
WHO. WHO standard: universal access to rapid tuberculosis diagnostics. World Health Organization https://www.who.int/publications/i/item/9789240071315 (2023).
Frascella, B. et al. Subclinical tuberculosis disease-a review and analysis of prevalence surveys to inform definitions, burden, associations, and screening methodology. Clin. Infect. Dis. 73, e830–e841 (2021).
pubmed: 32936877
doi: 10.1093/cid/ciaa1402
Kendall, E. A., Shrestha, S. & Dowdy, D. W. The epidemiological importance of subclinical tuberculosis. A critical reappraisal. Am. J. Respir. Crit. Care Med. 203, 168–174 (2021).
pubmed: 33197210
pmcid: 7874405
doi: 10.1164/rccm.202006-2394PP
Flynn, J. L. & Chan, J. Immune cell interactions in tuberculosis. Cell 185, 4682–4702 (2022). Comprehensive summary of the immunopathogenesis of TB.
pubmed: 36493751
doi: 10.1016/j.cell.2022.10.025
Domínguez, J. et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infect. Dis. 23, e122–e137 (2023).
pubmed: 36868253
doi: 10.1016/S1473-3099(22)00875-1
Mokrousov, I. et al. Molecular insight into Mycobacterium tuberculosis resistance to nitrofuranyl amides gained through metagenomics-like analysis of spontaneous mutants. Pharmaceuticals 15, 1136 (2022).
pubmed: 36145357
pmcid: 9504009
doi: 10.3390/ph15091136
Ghosh, A., N, S. & Saha, S. Survey of drug resistance associated gene mutations in Mycobacterium tuberculosis, ESKAPE and other bacterial species. Sci. Rep. 10, 8957 (2020).
pubmed: 32488120
pmcid: 7265455
doi: 10.1038/s41598-020-65766-8
Green, A. G. et al. Analysis of genome-wide mutational dependence in naturally evolving Mycobacterium tuberculosis populations. Mol. Biol. Evol. https://doi.org/10.1093/molbev/msad131 (2023).
Bergval, I. et al. Pre-existing isoniazid resistance, but not the genotype of Mycobacterium tuberculosis drives rifampicin resistance codon preference in vitro. PLoS ONE 7, e29108 (2012).
pubmed: 22235262
pmcid: 3250395
doi: 10.1371/journal.pone.0029108
David, H. L. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl. Microbiol. 20, 810–814 (1970).
pubmed: 4991927
pmcid: 377053
doi: 10.1128/am.20.5.810-814.1970
Dheda, K. et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir. Med. 5, 291–360 (2017).
doi: 10.1016/S2213-2600(17)30079-6
Ismail, N., Omar, S. V., Ismail, N. A. & Peters, R. P. H. Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis. Data Brief. 20, 1975–1983 (2018).
pubmed: 30306102
pmcid: 6172430
doi: 10.1016/j.dib.2018.09.057
Schena, E. et al. Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC™ MGIT™ 960 system. J. Antimicrob. Chemother. 71, 1532–1539 (2016).
pubmed: 27076101
doi: 10.1093/jac/dkw044
Davies Forsman, L. et al. Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China. Eur. Respir. J. 57, 2003463 (2021).
pubmed: 33154028
doi: 10.1183/13993003.03463-2020
Nguyen, Q. H., Contamin, L., Nguyen, T. V. A. & Bañuls, A. L. Insights into the processes that drive the evolution of drug resistance in Mycobacterium tuberculosis. Evol. Appl. 11, 1498–1511 (2018).
pubmed: 30344622
pmcid: 6183457
doi: 10.1111/eva.12654
Said, B. N. et al. Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosis. Int. J. Mycobacteriol. 10, 457–462 (2021).
pubmed: 34916467
pmcid: 7612567
doi: 10.4103/ijmy.ijmy_178_21
Kokesch-Himmelreich, J. et al. Do anti-tuberculosis drugs reach their target? — high-resolution matrix-assisted laser desorption/ionization mass spectrometry imaging provides information on drug penetration into necrotic granulomas. Anal. Chem. 94, 5483–5492 (2022).
pubmed: 35344339
doi: 10.1021/acs.analchem.1c03462
Strydom, N. et al. Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung lesions: a mechanistic model and tool for regimen and dose optimization. PLoS Med. 16, e1002773 (2019).
pubmed: 30939136
pmcid: 6445413
doi: 10.1371/journal.pmed.1002773
The CRyPTIC Consortium. A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics. PLoS Biol. 20, e3001721 (2022).
pmcid: 9363010
doi: 10.1371/journal.pbio.3001721
Miotto, P. et al. Transcriptional regulation and drug resistance in Mycobacterium tuberculosis. Front. Cell Infect. Microbiol. 12, 990312 (2022).
pubmed: 36118045
pmcid: 9480834
doi: 10.3389/fcimb.2022.990312
Koehler, N. et al. Pretomanid-resistant tuberculosis. J. Infect. 86, 520–524 (2023).
pubmed: 36738862
doi: 10.1016/j.jinf.2023.01.039
Heyckendorf, J. et al. What is resistance? Impact of phenotypic versus molecular drug resistance testing on therapy for multi- and extensively drug-resistant tuberculosis. Antimicrob. Agents Chemother. 62, e01550-17 (2018).
pubmed: 29133554
pmcid: 5786814
doi: 10.1128/AAC.01550-17
Tornheim, J. A. et al. Increased moxifloxacin dosing among patients with multidrug-resistant tuberculosis with low-level resistance to moxifloxacin did not improve treatment outcomes in a tertiary care center in Mumbai, India. Open. Forum Infect. Dis. 9, ofab615 (2022).
pubmed: 35097152
doi: 10.1093/ofid/ofab615
WHO Global Tuberculosis Programme. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. World Health Organization https://www.who.int/publications/i/item/9789240028173 (2021).
WHO Global Tuberculosis Programme. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. 2nd edn. World Health Organization https://www.who.int/publications/i/item/9789240082410#:~:Text=The%20catalogue%20provides%20a%20reference,countries%20for%20the%2013%20medicines (2023).
Maslov, D. A., Shur, K. V., Vatlin, A. A. & Danilenko, V. N. MmpS5–MmpL5 transporters provide Mycobacterium smegmatis resistance to imidazo[1,2-b][1,2,4,5]tetrazines. Pathogens 9, 166 (2020).
pubmed: 32121069
pmcid: 7157563
doi: 10.3390/pathogens9030166
Radhakrishnan, A. et al. Crystal structure of the transcriptional regulator Rv0678 of Mycobacterium tuberculosis. J. Biol. Chem. 289, 16526–16540 (2014).
pubmed: 24737322
pmcid: 4047419
doi: 10.1074/jbc.M113.538959
Vatlin, A. A. et al. Transcriptomic profile of Mycobacterium smegmatis in response to an Imidazo[1,2-b][1,2,4,5]tetrazine reveals its possible impact on iron metabolism. Front. Microbiol. 12, 724042 (2021).
pubmed: 34421882
pmcid: 8371482
doi: 10.3389/fmicb.2021.724042
Asaad, M. et al. Methylation in Mycobacterium–host interaction and implications for novel control measures. Infect. Genet. Evol. 83, 104350 (2020).
pubmed: 32380312
doi: 10.1016/j.meegid.2020.104350
Fatima, S. et al. Epigenetic code during mycobacterial infections: therapeutic implications for tuberculosis. FEBS J. 289, 4172–4191 (2022).
pubmed: 34453865
doi: 10.1111/febs.16170
Peters, J. S. et al. Genetic diversity in Mycobacterium tuberculosis clinical isolates and resulting outcomes of tuberculosis infection and disease. Annu. Rev. Genet. 54, 511–537 (2020).
pubmed: 32926793
doi: 10.1146/annurev-genet-022820-085940
Chu, H., Hu, Y., Zhang, B., Sun, Z. & Zhu, B. DNA methyltransferase HsdM induce drug resistance on Mycobacterium tuberculosis via multiple effects. Antibiotics 10, 1544 (2021).
pubmed: 34943756
pmcid: 8698436
doi: 10.3390/antibiotics10121544
Hu, X. et al. The mycobacterial DNA methyltransferase HsdM decreases intrinsic isoniazid susceptibility. Antibiotics 10, 1323 (2021).
pubmed: 34827261
pmcid: 8614780
doi: 10.3390/antibiotics10111323
Li, H. C. et al. Genome-wide DNA methylation and transcriptome and proteome changes in Mycobacterium tuberculosis with para-aminosalicylic acid resistance. Chem. Biol. Drug Des. 95, 104–112 (2020).
pubmed: 31562690
doi: 10.1111/cbdd.13625
Wu, Z. et al. mbtD and celA1 association with ethambutol resistance in Mycobacterium tuberculosis: a multiomics analysis. Front. Cell. Infect. Microbiol. 12, 959911 (2022).
pubmed: 36118032
pmcid: 9471152
doi: 10.3389/fcimb.2022.959911
Wong, S. Y. et al. Functional role of methylation of G518 of the 16S rRNA 530 loop by GidB in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 57, 6311–6318 (2013).
pubmed: 24100503
pmcid: 3837903
doi: 10.1128/AAC.00905-13
Manosuthi, W., Wiboonchutikul, S. & Sungkanuparph, S. Integrated therapy for HIV and tuberculosis. AIDS Res. Ther. 13, 22 (2016).
pubmed: 27182275
pmcid: 4866405
doi: 10.1186/s12981-016-0106-y
Svensson, E. M. et al. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob. Agents Chemother. 57, 2780–2787 (2013).
pubmed: 23571542
pmcid: 3716161
doi: 10.1128/AAC.00191-13
Svensson, E. M., Dooley, K. E. & Karlsson, M. O. Impact of lopinavir–ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis–HIV coinfection. Antimicrob. Agents Chemother. 58, 6406–6412 (2014).
pubmed: 25114140
pmcid: 4249405
doi: 10.1128/AAC.03246-14
Haas, D. W. et al. Pharmacogenetics of between-individual variability in plasma clearance of bedaquiline and clofazimine in South Africa. J. Infect. Dis. 226, 147–156 (2022).
pubmed: 35091749
pmcid: 9373148
doi: 10.1093/infdis/jiac024
Svensson, E. M. & Karlsson, M. O. Modelling of mycobacterial load reveals bedaquiline’s exposure–response relationship in patients with drug-resistant TB. J. Antimicrob. Chemother. 72, 3398–3405 (2017).
pubmed: 28961790
pmcid: 5890768
doi: 10.1093/jac/dkx317
Tanneau, L., Karlsson, M. O. & Svensson, E. M. Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis. Br. J. Clin. Pharmacol. 86, 913–922 (2020).
pubmed: 31840278
pmcid: 7163373
doi: 10.1111/bcp.14199
Tanneau, L. et al. Population pharmacokinetics of delamanid and its main metabolite DM-6705 in drug-resistant tuberculosis patients receiving delamanid alone or coadministered with bedaquiline. Clin. Pharmacokinet. 61, 1177–1185 (2022).
pubmed: 35668346
pmcid: 9349160
doi: 10.1007/s40262-022-01133-2
Guglielmetti, L. et al. QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study. Eur. Respir. J. 52, 1800537 (2018).
pubmed: 29880656
doi: 10.1183/13993003.00537-2018
Shimokawa, Y., Sasahara, K., Yoda, N., Mizuno, K. & Umehara, K. Delamanid does not inhibit or induce cytochrome P450 enzymes in vitro. Biol. Pharm. Bull. 37, 1727–1735 (2014).
pubmed: 25366478
doi: 10.1248/bpb.b14-00311
Tanneau, L. et al. Assessing prolongation of the corrected QT interval with bedaquiline and delamanid coadministration to predict the cardiac safety of simplified dosing regimens. Clin. Pharmacol. Ther. 112, 873–881 (2022).
pubmed: 35687528
pmcid: 9474693
doi: 10.1002/cpt.2685
Dooley, K. E. et al. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrob. Agents Chemother. 58, 5245–5252 (2014).
pubmed: 24957823
pmcid: 4135849
doi: 10.1128/AAC.03332-14
TB Alliance. SimpliciTB results and heapatic safety of pretomanid regimens +/− pyrazinamide. TB Alliance https://www.croiconference.org/abstract/simplicitb-results-and-hepatic-safety-of-pretomanid-regimens-pyrazinamide/#:~:Text=Conclusions%3A,6%2D7%25%20of%20patients (2023).
Wasserman, S. et al. Linezolid pharmacokinetics in South African patients with drug-resistant tuberculosis and a high prevalence of HIV coinfection. Antimicrob. Agents Chemother. 63, e02164-18 (2019).
pubmed: 30617089
pmcid: 6395899
doi: 10.1128/AAC.02164-18
Imperial, M. Z., Nedelman, J. R., Conradie, F. & Savic, R. M. Proposed linezolid dosing strategies to minimize adverse events for treatment of extensively drug-resistant tuberculosis. Clin. Infect. Dis. 74, 1736–1747 (2022).
pubmed: 34604901
doi: 10.1093/cid/ciab699
Wasserman, S., Meintjes, G. & Maartens, G. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index. Expert Rev. Anti Infect. Ther. 14, 901–915 (2016).
pubmed: 27532292
doi: 10.1080/14787210.2016.1225498
Wilby, K. J. & Hussain, F. N. A review of clinical pharmacokinetic and pharmacodynamic relationships and clinical implications for drugs used to treat multi-drug resistant tuberculosis. Eur. J. Drug Metab. Pharmacokinet. 45, 305–313 (2020).
pubmed: 31925745
doi: 10.1007/s13318-019-00604-5
Cegielski, J. P. et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin. Infect. Dis. 59, 1049–1063 (2014).
pubmed: 25057101
pmcid: 4184341
doi: 10.1093/cid/ciu572
Hoffmann, H. et al. Delamanid and bedaquiline resistance in Mycobacterium tuberculosis ancestral beijing genotype causing extensively drug-resistant tuberculosis in a tibetan refugee. Am. J. Respir. Crit. Care Med. 193, 337–340 (2016).
pubmed: 26829425
doi: 10.1164/rccm.201502-0372LE
Ye, M. et al. Antibiotic heteroresistance in Mycobacterium tuberculosis isolates: a systematic review and meta-analysis. Ann. Clin. Microb. Antimicrob. 20, 73 (2021).
doi: 10.1186/s12941-021-00478-z
Ng, K. C. S. et al. How well do routine molecular diagnostics detect rifampin heteroresistance in Mycobacterium tuberculosis? J. Clin. Microbiol. 57, e00717–e00719 (2019).
pubmed: 31413081
pmcid: 6812990
doi: 10.1128/JCM.00717-19
Gagneux, S. Fitness cost of drug resistance in Mycobacterium tuberculosis. Clin. Microbiol. Infect. 15 (Suppl. 1), 66–68 (2009).
pubmed: 19220360
doi: 10.1111/j.1469-0691.2008.02685.x
Casali, N. et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat. Genet. 46, 279–286 (2014).
pubmed: 24464101
pmcid: 3939361
doi: 10.1038/ng.2878
Merker, M. et al. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nat. Genet. 47, 242–249 (2015).
pubmed: 25599400
doi: 10.1038/ng.3195
Zhao, Y. et al. National survey of drug-resistant tuberculosis in China. N. Engl. J. Med. 366, 2161–2170 (2012).
pubmed: 22670902
doi: 10.1056/NEJMoa1108789
Gagneux, S. et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog. 2, e61 (2006).
pubmed: 16789833
pmcid: 1479046
doi: 10.1371/journal.ppat.0020061
Dheda, K., Makambwa, E. & Esmail, A. The great masquerader: tuberculosis presenting as community-acquired pneumonia. Semin. Respir. Crit. Care Med. 41, 592–604 (2020).
pubmed: 32564347
doi: 10.1055/s-0040-1710583
Sossen, B. et al. The natural history of untreated pulmonary tuberculosis in adults: a systematic review and meta-analysis. Lancet Respir. Med. 11, 367–379 (2023).
pubmed: 36966795
doi: 10.1016/S2213-2600(23)00097-8
WHO. Optimizing active case-finding for tuberculosis: implementation lessons from South-East Asia. World Health Organization https://www.who.int/publications/i/item/9789290228486 (2021).
Esmail, A. et al. Comparison of two diagnostic intervention packages for community-based active case finding for tuberculosis: an open-label randomized controlled trial. Nat. Med. 29, 1009–1016 (2023). Validation of an ACF model using a mobile van shows that portable PCR technology can be used to effectively diagnose DR-TB in the community.
pubmed: 36894651
doi: 10.1038/s41591-023-02247-1
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04303104?term=NCT04303104&rank=1 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT01990274?term=NCT01990274&rank=1 (2015).
Gilpin, C., Korobitsyn, A. & Weyer, K. Current tools available for the diagnosis of drug-resistant tuberculosis. Ther. Adv. Infect. Dis. 3, 145–151 (2016).
pubmed: 28386407
pmcid: 5375090
Technical Manual for Drug Susceptibility Testing of Medicines Used in the Treatment of Tuberculosis. Report NO. 9789241514842 (WHO, 2018).
WHO. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update. World Health Organization https://www.ncbi.nlm.nih.gov/books/NBK258608/ (2013).
Theron, G. et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 383, 424–435 (2014).
pubmed: 24176144
doi: 10.1016/S0140-6736(13)62073-5
Köser, C. U. et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N. Engl. J. Med. 369, 290–292 (2013).
pubmed: 23863072
doi: 10.1056/NEJMc1215305
Walker, T. M. et al. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis. Lancet Microbe 3, e265–e273 (2022).
pubmed: 35373160
pmcid: 7612554
doi: 10.1016/S2666-5247(21)00301-3
Feuerriegel, S. et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. Eur. Respir. J. 57, 2001796 (2021).
pubmed: 32764113
doi: 10.1183/13993003.01796-2020
Kambli, P. et al. Targeted next generation sequencing directly from sputum for comprehensive genetic information on drug resistant Mycobacterium tuberculosis. Tuberculosis 127, 102051 (2021).
pubmed: 33450448
doi: 10.1016/j.tube.2021.102051
Wu, S. H., Xiao, Y. X., Hsiao, H. C. & Jou, R. Development and assessment of a novel whole-gene-based targeted next-generation sequencing assay for detecting the susceptibility of Mycobacterium tuberculosis to 14 drugs. Microbiol. Spectr. 10, e0260522 (2022).
pubmed: 36255328
doi: 10.1128/spectrum.02605-22
Allix-Béguec, C. et al. Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing. N. Engl. J. Med. 379, 1403–1415 (2018).
pubmed: 30280646
doi: 10.1056/NEJMoa1800474
Walker, T. M. et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect. Dis. 15, 1193–1202 (2015).
pubmed: 26116186
pmcid: 4579482
doi: 10.1016/S1473-3099(15)00062-6
Grobbel, H. P. et al. Design of multidrug-resistant tuberculosis treatment regimens based on DNA sequencing. Clin. Infect. Dis. 73, 1194–1202 (2021).
pubmed: 33900387
pmcid: 8492214
doi: 10.1093/cid/ciab359
Manson, A. L. et al. Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance. Nat. Genet. 49, 395–402 (2017).
pubmed: 28092681
pmcid: 5402762
doi: 10.1038/ng.3767
O’Donnell, M. Isoniazid monoresistance: a precursor to multidrug-resistant tuberculosis. Ann. Am. Thorac. Soc. 15, 306–307 (2018).
pubmed: 29493332
pmcid: 5880525
doi: 10.1513/AnnalsATS.201711-885ED
Donald, P. R. et al. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur. J. Clin. Pharmacol. 63, 633–639 (2007).
pubmed: 17505821
doi: 10.1007/s00228-007-0305-5
Pasipanodya, J. G. & Gumbo, T. A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. Clin. Infect. Dis. 57, 21–31 (2013).
pubmed: 23487389
pmcid: 3669525
doi: 10.1093/cid/cit167
Sarathy, J. P. et al. Extreme drug tolerance of Mycobacterium tuberculosis in caseum. Antimicrob. Agents Chemother. 62, e02266–e02317 (2018).
pubmed: 29203492
pmcid: 5786764
doi: 10.1128/AAC.02266-17
Rockwood, N. et al. Low frequency of acquired isoniazid and rifampicin resistance in rifampicin-susceptible pulmonary tuberculosis in a setting of high HIV-1 infection and tuberculosis coprevalence. J. Infect. Dis. 216, 632–640 (2017).
pubmed: 28934422
pmcid: 5815623
doi: 10.1093/infdis/jix337
Vree, M. et al. Survival and relapse rate of tuberculosis patients who successfully completed treatment in Vietnam. Int. J. Tuberc. Lung Dis. 11, 392–397 (2007).
pubmed: 17394684
Fregonese, F. et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir. Med. 6, 265–275 (2018).
pubmed: 29595509
pmcid: 9017096
doi: 10.1016/S2213-2600(18)30078-X
Ragonnet, R., Trauer, J. M., Denholm, J. T., Marais, B. J. & McBryde, E. S. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from. BMC Infect. Dis. 17, 36 (2017).
pubmed: 28061832
pmcid: 5217596
doi: 10.1186/s12879-016-2171-1
WHO. Tuberculosis preventive treatment: rapid communication. World Health Organization https://www.who.int/publications/i/item/9789240089723 (2024).
Polesky, A. et al. Rifampin preventive therapy for tuberculosis in Boston’s homeless. Am. J. Respir. Crit. Care Med. 154, 1473–1477 (1996).
pubmed: 8912767
doi: 10.1164/ajrccm.154.5.8912767
Australian New Zealand Clinical Trials Registry. The V-QUIN MDR TRIAL: A Randomized Controlled Trial of Six Months of Daily Levofloxacin for the Prevention of Tuberculosis Among Household Contacts of Patients with Multi-Drug Resistant Tuberculosis. https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369817 (2019).
ISRCTN registry. Tuberculosis Child Multidrug-Resistant Preventive Therapy: TB CHAMP trial. https://www.isrctn.com/ISRCTN92634082 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03568383?term=NCT03568383&rank=1 (2023).
Tait, D. R. et al. Final analysis of a trial of M72/AS01(E) vaccine to prevent tuberculosis. N. Engl. J. Med. 381, 2429–2439 (2019). Phase II(b) study showing that the M72 vaccine had a 50% efficacy in preventing the development of active TB. This will have implications for reducing both DS-TB and DR-TB burden.
pubmed: 31661198
doi: 10.1056/NEJMoa1909953
Lazarchik, A., Nyaruhirira, A. U., Chiang, C. Y., Wares, F. & Horsburgh, C. R. Global availability of susceptibility testing for second-line anti-tuberculosis agents. Int. J. Tuberc. Lung Dis. 26, 524–528 (2022).
pubmed: 35650708
doi: 10.5588/ijtld.21.0420
Nahid, P. et al. Treatment of drug-resistant tuberculosis. an official ATS/CDC/ERS/IDSA clinical practice guideline. Am. J. Respir. Crit. Care Med. 200, e93–e142 (2019).
pubmed: 31729908
pmcid: 6857485
doi: 10.1164/rccm.201909-1874ST
NICE. Tuberculosis: NICE guideline 33. National Institute for Health and Care Excellence https://www.nice.org.uk/guidance/ng33 (2016).
Dorman, S. E. et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N. Engl. J. Med. 384, 1705–1718 (2021).
pubmed: 33951360
pmcid: 8282329
doi: 10.1056/NEJMoa2033400
WHO. WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. World Health Organization https://www.who.int/publications/i/item/9789240065116 (2022).
Turkova, A. et al. Shorter treatment for nonsevere tuberculosis in African and Indian children. N. Engl. J. Med. 386, 911–922 (2022).
pubmed: 35263517
pmcid: 7612496
doi: 10.1056/NEJMoa2104535
WHO. WHO consolidated guidelines on tuberculosis: Module 4: treatment: drug-susceptible tuberculosis treatment. World Health Organization https://www.who.int/publications/i/item/9789240048126 (2022).
Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis (WHO, 2008).
Lan, Z. et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir. Med. 8, 383–394 (2020).
pubmed: 32192585
pmcid: 7384398
doi: 10.1016/S2213-2600(20)30047-3
Nunn, A. J. et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N. Engl. J. Med. 380, 1201–1213 (2019). Randomized controlled trial showing that a shorter 9- to 11-month injection-based regimen had similar outcomes to the longer 18- to 20-month injection-based regimen. This established the foundational basis for treatment shortening.
pubmed: 30865791
doi: 10.1056/NEJMoa1811867
Conradie, F. et al. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N. Engl. J. Med. 387, 810–823 (2022). Demonstrates that the BPaL regimen performed well in patients with pre-XDR-TB, XDR-TB and MDR-TB treatment failures.
pubmed: 36053506
pmcid: 9490302
doi: 10.1056/NEJMoa2119430
Conradie, F. et al. Treatment of highly drug-resistant pulmonary tuberculosis. N. Engl. J. Med. 382, 893–902 (2020).
pubmed: 32130813
pmcid: 6955640
doi: 10.1056/NEJMoa1901814
Esmail, A. et al. An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT Study). Am. J. Respir. Crit. Care Med. 205, 1214–1227 (2022). RCT of 6-month all-oral regimen for MDR-TB demonstrating the ability of such a regimen to improve outcomes within the context of a controlled trial.
pubmed: 35175905
doi: 10.1164/rccm.202107-1779OC
Ndjeka, N. et al. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. Lancet Infect. Dis. 22, 1042–1051 (2022).
pubmed: 35512718
pmcid: 9217754
doi: 10.1016/S1473-3099(21)00811-2
Nyang’wa, B. T. et al. A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N. Engl. J. Med. 387, 2331–2343 (2022). Demonstration that an all-oral 6-month regimen (BPaLM) produced equivalent outcomes, and with reduced adverse effects, to a longer injectable-containing control regimen.
pubmed: 36546625
doi: 10.1056/NEJMoa2117166
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT02333799?term=NCT02333799&rank=1 (2020).
Gupta, A. et al. Lifesaving, cost-saving: innovative simplified regimens for drug-resistant tuberculosis. PLoS Glob. Public Health 2, e0001287 (2022).
pubmed: 36962626
pmcid: 10021682
doi: 10.1371/journal.pgph.0001287
Esmail, A., Sabur, N. F., Okpechi, I. & Dheda, K. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. J. Thorac. Dis. 10, 3102–3118 (2018).
pubmed: 29997980
pmcid: 6006072
doi: 10.21037/jtd.2018.05.11
Pasipanodya, J. G. et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J. Infect. Dis. 208, 1464–1473 (2013).
pubmed: 23901086
pmcid: 3789573
doi: 10.1093/infdis/jit352
Sekaggya-Wiltshire, C. et al. The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs. Tuberculosis 108, 77–82 (2018).
pubmed: 29523331
doi: 10.1016/j.tube.2017.11.004
Mota, L. et al. Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis. Int. J. Tuberc. Lung Dis. 20, 819–826 (2016).
pubmed: 27155187
doi: 10.5588/ijtld.15.0803
Boeree, M. J. et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 191, 1058–1065 (2015).
pubmed: 25654354
doi: 10.1164/rccm.201407-1264OC
Mallick, J. S., Nair, P., Abbew, E. T., Van Deun, A. & Decroo, T. Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review. JAC Antimicrob. Resist. 4, dlac029 (2022).
pubmed: 35356403
pmcid: 8963286
doi: 10.1093/jacamr/dlac029
Pai, H. et al. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis. BMC Infect. Dis. 22, 870 (2022).
pubmed: 36414938
pmcid: 9682840
doi: 10.1186/s12879-022-07861-x
Kamp, J. et al. Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. Int. J. Antimicrob. Agents 49, 688–694 (2017).
pubmed: 28389352
doi: 10.1016/j.ijantimicag.2017.01.017
Rao, P. S. et al. Alternative methods for therapeutic drug monitoring and dose adjustment of tuberculosis treatment in clinical settings: a systematic review. Clin. Pharmacokinet. 62, 375–398 (2023).
pubmed: 36869170
pmcid: 10042915
doi: 10.1007/s40262-023-01220-y
Lange, C., Kohler, N. & Gunther, G. Regimens for drug-resistant tuberculosis. N. Engl. J. Med. 388, 190 (2023).
pubmed: 36630637
Dheda, K., Gumbo, T., Lange, C., Horsburgh, C. R. Jr. & Furin, J. Pan-tuberculosis regimens: an argument against. Lancet Respir. Med. 6, 240–242 (2018).
pubmed: 29595502
doi: 10.1016/S2213-2600(18)30097-3
Lange, C. et al. Perspective for precision medicine for tuberculosis. Front. Immunol. 11, 566608 (2020).
pubmed: 33117351
pmcid: 7578248
doi: 10.3389/fimmu.2020.566608
Heyckendorf, J. et al. Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. Eur. Respir. J. 58, 2003492 (2021).
pubmed: 33574078
doi: 10.1183/13993003.03492-2020
DiNardo, A. R. et al. Gene expression signatures identify biologically and clinically distinct tuberculosis endotypes. Eur. Respir. J. 60, 2102263 (2022).
pubmed: 35169026
pmcid: 9474892
doi: 10.1183/13993003.02263-2021
International Standards for Tubcerculosis Care. 3rd edn (TB CARE I, 2014).
Chesov, D. et al. Failing treatment of multidrug-resistant tuberculosis: a matter of definition. Int. J. Tuberc. Lung Dis. 23, 522–524 (2019).
pubmed: 31064633
doi: 10.5588/ijtld.18.0756
Butov, D. et al. Multidrug-resistant tuberculosis in the Kharkiv region, Ukraine. Int. J. Tuberc. Lung Dis. 24, 485–491 (2020).
pubmed: 32398197
doi: 10.5588/ijtld.19.0508
Chesov, D. et al. Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country. Eur. Respir. J. 57, 2002544 (2021).
pubmed: 33334942
doi: 10.1183/13993003.02544-2020
Heyckendorf, J. et al. Relapse-free cure from multidrug-resistant tuberculosis in Germany. Eur. Respir. J. 51, 1702122 (2018).
pubmed: 29467205
doi: 10.1183/13993003.02122-2017
Maier, C. et al. Long-term treatment outcomes in patients with multidrug-resistant tuberculosis. Clin. Microbiol. Infect. 29, 751–757 (2023).
pubmed: 36842637
doi: 10.1016/j.cmi.2023.02.013
Otto-Knapp, R. et al. Long-term multidrug- and rifampicin-resistant tuberculosis treatment outcome by new WHO definitions in Germany. Eur. Respir. J. 60, 2200765 (2022).
pubmed: 36423919
doi: 10.1183/13993003.00765-2022
Fox, G. J. et al. Surgery as an adjunctive treatment for multidrug-resistant tuberculosis: an individual patient data metaanalysis. Clin. Infect. Dis. 62, 887–895 (2016).
pubmed: 26757804
doi: 10.1093/cid/ciw002
Calligaro, G. L. et al. Outcomes of patients undergoing lung resection for drug-resistant TB and the prognostic significance of pre-operative positron emission tomography/computed tomography (PET/CT) in predicting treatment failure. EClinicalMedicine 55, 101728 (2023).
pubmed: 36386040
doi: 10.1016/j.eclinm.2022.101728
Myburgh, H. et al. A scoping review of patient-centred tuberculosis care interventions: gaps and opportunities. PLoS Glob. Public Health 3, e0001357 (2023).
pubmed: 36963071
pmcid: 10021744
doi: 10.1371/journal.pgph.0001357
Ethics Guidance for the Implementation of the End TB Strategy (WHO, 2017).
Connor, S. R. Palliative care for tuberculosis. J. Pain. Symptom Manag. 55, S178–S180 (2018).
doi: 10.1016/j.jpainsymman.2017.03.019
WHO. Palliative care fact sheet. World Health Organization https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/palliative-care/palliative-care-essential-facts.pdf?sfvrsn=c5fed6dc_1 (2020).
ECDC. European Union standards for tuberculosis care - 2017 update. European Centre for Disease Prevention and Control https://www.ecdc.europa.eu/en/publications-data/european-union-standards-tuberculosis-care-2017-update (2018).
Migliori, G. B., Sotgiu, G., Rosales-Klintz, S. & van der Werf, M. J. European Union standard for tuberculosis care on treatment of multidrug-resistant tuberculosis following new World Health Organization recommendations. Eur. Respir. J. 52, 1801617 (2018).
pubmed: 30209200
doi: 10.1183/13993003.01617-2018
Agins, B. D. et al. Improving the cascade of global tuberculosis care: moving from the “what” to the “how” of quality improvement. Lancet Infect. Dis. 19, e437–e443 (2019).
pubmed: 31447305
doi: 10.1016/S1473-3099(19)30420-7
Cobelens, F., van Kampen, S., Ochodo, E., Atun, R. & Lienhardt, C. Research on implementation of interventions in tuberculosis control in low- and middle-income countries: a systematic review. PLoS Med. 9, e1001358 (2012).
pubmed: 23271959
pmcid: 3525528
doi: 10.1371/journal.pmed.1001358
Batalden, M. et al. Coproduction of healthcare service. BMJ Qual. Saf. 25, 509–517 (2016).
pubmed: 26376674
doi: 10.1136/bmjqs-2015-004315
Pai, M., Yadav, P. & Anupindi, R. Tuberculosis control needs a complete and patient-centric solution. Lancet Glob. Health 2, e189–e190 (2014).
pubmed: 25103049
doi: 10.1016/S2214-109X(14)70198-6
Grimsrud, A. et al. Reimagining HIV service delivery: the role of differentiated care from prevention to suppression. J. Int. AIDS Soc. 19, 21484 (2016).
pubmed: 27914186
pmcid: 5136137
doi: 10.7448/IAS.19.1.21484
Pai, M., Schumacher, S. G. & Abimbola, S. Surrogate endpoints in global health research: still searching for killer apps and silver bullets? BMJ Glob. Health 3, e000755 (2018).
pubmed: 29607104
pmcid: 5873542
doi: 10.1136/bmjgh-2018-000755
Bouchet, B., Francisco, M. & Ovretveit, J. The Zambia quality assurance program: successes and challenges. Int. J. Qual. Health Care 14 (Suppl. 1), 89–95 (2002).
pubmed: 12572792
doi: 10.1093/intqhc/14.suppl_1.89
Fan, H. et al. Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ann. Transl. Med. 9, 390 (2021).
pubmed: 33842611
pmcid: 8033376
doi: 10.21037/atm-20-4576
Taylor, J. et al. Residual respiratory disability after successful treatment of pulmonary tuberculosis: a systematic review and meta-analysis. EClinicalMedicine 59, 101979 (2023). Demonstrates that there was significant pulmonary disability after successful treatment of pulmonary tuberculosis highlighting this condition as a non-communicable disease of global epidemic proportions.
pubmed: 37205923
pmcid: 10189364
doi: 10.1016/j.eclinm.2023.101979
Byrne, A. L. et al. Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis. ERJ Open Res. 3, 00026-2017 (2017).
pubmed: 28717643
pmcid: 5507160
doi: 10.1183/23120541.00026-2017
de Vallière, S. & Barker, R. D. Residual lung damage after completion of treatment for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 8, 767–771 (2004).
pubmed: 15182148
Ivanova, O., Hoffmann, V. S., Lange, C., Hoelscher, M. & Rachow, A. Post-tuberculosis lung impairment: systematic review and meta-analysis of spirometry data from 14 621 people. Eur. Respir. Rev. 32, 220221 (2023).
pubmed: 37076175
pmcid: 10113954
doi: 10.1183/16000617.0221-2022
Sharma, N. et al. A comparison of patient treatment pathways among multidrug-resistant and drug-sensitive TB cases in Delhi, India: a cross-sectional study. Indian J. Tuberculosis 67, 502–508 (2020).
doi: 10.1016/j.ijtb.2020.07.020
Lee, G. et al. Impact of mental disorders on active TB treatment outcomes: a systematic review and meta-analysis. Int. J. Tuberc. Lung Dis. 24, 1279–1284 (2020).
pubmed: 33317672
doi: 10.5588/ijtld.20.0458
Ragan, E. J. et al. The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis. Int. J. Tuberc. Lung Dis. 24, 73–82 (2020).
pubmed: 32005309
doi: 10.5588/ijtld.19.0080
Pietersen, E. et al. Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa. PLoS ONE 18, e0281097 (2023).
pubmed: 36780443
pmcid: 9925007
doi: 10.1371/journal.pone.0281097
Ashley-Norman, P. Balancing tuberculosis therapy and substance use. Lancet Infect. Dis. 23, 542 (2023).
doi: 10.1016/S1473-3099(23)00194-9
UN. Resolution adopted by the General Assembly on 25 September 2015. 70/1. Transforming our world: the 2030 Agenda for Sustainable Development. United Nations https://www.un.org/en/development/desa/population/migration/generalassembly/docs/globalcompact/A_RES_70_1_E.pdf (2015).
WHO. The end TB strategy (WHO, 2015).
Dheda, K. et al. Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. Lancet Respir. Med. 5, 269–281 (2017).
pubmed: 28109869
doi: 10.1016/S2213-2600(16)30433-7
Dheda, K. & Migliori, G. B. The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue. Lancet 379, 773–775 (2012).
pubmed: 22033020
doi: 10.1016/S0140-6736(11)61062-3
Behr, M. A., Edelstein, P. H. & Ramakrishnan, L. Is Mycobacterium tuberculosis infection life long? BMJ 367, l5770 (2019).
pubmed: 31649096
pmcid: 6812595
doi: 10.1136/bmj.l5770
Menzies, D., Gardiner, G., Farhat, M., Greenaway, C. & Pai, M. Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Int. J. Tuberc. Lung Dis. 12, 498–505 (2008).
pubmed: 18419884
Curry International Tuberculosis Center & State of California Department of Public Health Tuberculosis Control Branch. Drug-resistant Tuberculosis: A Survival Guide for Clinicians. 3rd edn (2016).
Diacon, A. H. et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob. Agents Chemother. 56, 3027–3031 (2012).
pubmed: 22430968
pmcid: 3370777
doi: 10.1128/AAC.06125-11
Lange, C. et al. Management of patients with multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 23, 645–662 (2019).
pubmed: 31315696
doi: 10.5588/ijtld.18.0622
Li, M. et al. Phase 1 study of the effects of the tuberculosis treatment pretomanid, alone and in combination with moxifloxacin, on the QTc interval in healthy volunteers. Clin. Pharmacol. Drug Dev. 10, 634–646 (2021).
pubmed: 33378139
doi: 10.1002/cpdd.898
Liu, Y. et al. Safety and pharmacokinetic profile of pretomanid in healthy Chinese adults: results of a phase I single dose escalation study. Pulm. Pharmacol. Ther. 73–74, 102132 (2022).
pubmed: 35595003
doi: 10.1016/j.pupt.2022.102132
WHO. Use of targeted next-generation sequencing to detect drug-resistant tuberculosis: rapid communication, July 2023. World Health Organization https://www.who.int/publications/i/item/9789240076372 (2023).
Meeting Report of the WHO Expert Consultation on the Definition of Extensively Drug-Resistant Tuberculosis, 27–29 October 2020. Report No. 9789240018662 (electronic version) 9789240018679 (print version) (WHO, 2021).
Campbell, J. R. et al. Low body mass index at treatment initiation and rifampicin-resistant tuberculosis treatment outcomes: an individual participant data meta-analysis. Clin. Infect. Dis. 75, 2201–2210 (2022).
pubmed: 35476134
doi: 10.1093/cid/ciac322
Golightly, L. K. et al. Renal Pharmacotherapy. Dosage Adjustment of Medications Eliminated by the Kidneys (Springer, 2013).
Huynh, D. & Nguyen, N. Q. in Diet and Nutrition in Critical Care (eds Rajendram, R., Preedy, V. R. & Patel V. B.) (Springer, 2015).
Maugans, C. et al. Best practices for the care of pregnant people living with TB. Int. J. Tuberc. Lung Dis. 27, 357–366 (2023).
pubmed: 37143222
pmcid: 10171489
doi: 10.5588/ijtld.23.0031
Winter, M. A., Guhr, K. N. & Berg, G. M. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft–Gault equation. Pharmacotherapy 32, 604–612 (2012).
pubmed: 22576791
doi: 10.1002/j.1875-9114.2012.01098.x
WHO. Consensus meeting report: development of a target product profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease. World Health Organization https://www.who.int/publications/i/item/WHO-HTM-TB-2017.18 (2017).
WHO. Definitions. World Health Organization https://tbksp.org/en/node/1882 (2023).
Musonda, H. K., Rose, P. C., Switala, J. & Schaaf, H. S. Paediatric admissions to a TB hospital: reasons for admission, clinical profile and outcomes. Int. J. Tuberc. Lung Dis. 26, 217–223 (2022).
pubmed: 35197161
doi: 10.5588/ijtld.21.0538
Global Fund. List of tuberculosis pharmaceutical products classified according to the global fund quality assurance policy. The Global Fund https://www.theglobalfund.org/media/4757/psm_productstb_list_en.pdf (2023).
WHO. Use of bedaquiline in children and adolescents with multidrug- and rifampicin-resistant tuberculosis: information note. World Health Organization https://www.who.int/publications/i/item/9789240074286 (2023).
WHO. Use of delamanid in children and adolescents with multidrug- and rifampicin-resistant tuberculosis: information note. World Health Organization https://www.who.int/publications/i/item/9789240074309 (2023).
WHO. WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents. World Health Organization https://www.who.int/publications/i/item/9789240046764 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04062201?term=NCT04062201&rank=1 (2022).
Patankar, S. et al. Making the case for all-oral, shorter regimens for children with drug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 208, 130–131 (2023).
pubmed: 37276531
pmcid: 10395497
doi: 10.1164/rccm.202304-0670VP
The Sentinel Project for Pediatric Drug-Resistant Tuberculosis. Management of Drug-Resistant Tuberculosis In Children: A Field Guide (Boston, 2021).
endTB Consortium. endTB clinical trial results. endTB https://endtb.org/endtb-clinical-trial-results (2023).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT02754765 (2023).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT02589782?term=NCT02589782&rank=1 (2021).
Mvelase, N. R. & Mlisana, K. P. Xpert MTB/XDR for rapid detection of drug-resistant tuberculosis beyond rifampicin. Lancet Infect. Dis. 22, 156–157 (2022).
pubmed: 34627495
doi: 10.1016/S1473-3099(21)00481-3
Chesov, E. et al. Emergence of bedaquiline resistance in a high tuberculosis burden country. Eur. Respir. J. 59, 2100621 (2022).
pubmed: 34503982
pmcid: 8943268
doi: 10.1183/13993003.00621-2021
Ghodousi, A. et al. Acquisition of cross-resistance to bedaquiline and clofazimine following treatment for tuberculosis in Pakistan. Antimicrob. Agents Chemother. 63, e00915-19 (2019).
pubmed: 31262765
pmcid: 6709449
doi: 10.1128/AAC.00915-19
Lange, C., Vasiliu, A. & Mandalakas, A. M. Emerging bedaquiline-resistant tuberculosis. Lancet Microbe 4, e964–e965 (2023).
pubmed: 37931639
doi: 10.1016/S2666-5247(23)00321-X
Holt, E. Phase 2 trial of a novel tuberculosis drug launched. Lancet Microbe https://doi.org/10.1016/S2666-5247(23)00401-9 (2024).
doi: 10.1016/S2666-5247(23)00401-9
pubmed: 38387472
pmcid: 10914669
Mok, J. et al. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea. Lancet 400, 1522–1530 (2022).
pubmed: 36522208
doi: 10.1016/S0140-6736(22)01883-9
Motta, I. et al. Recent advances in the treatment of tuberculosis. Clin. Microbiol. Infect. https://doi.org/10.1016/j.cmi.2023.07.013 (2023).
doi: 10.1016/j.cmi.2023.07.013
pubmed: 37482332
Goodall, R. L. et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet 400, 1858–1868 (2022).
pubmed: 36368336
pmcid: 7614824
doi: 10.1016/S0140-6736(22)02078-5
Padmapriyadarsini, C. et al. Bedaquiline, delamanid, linezolid, and clofazimine for treatment of pre-extensively drug-resistant tuberculosis. Clin. Infect. Dis. 76, e938–e946 (2022).
pubmed: 35767251
pmcid: 9907500
doi: 10.1093/cid/ciac528
Boeree, M. J. et al. UNITE4TB: a new consortium for clinical drug and regimen development for TB. Int. J. Tuberc. Lung Dis. 25, 886–889 (2021).
pubmed: 34686229
pmcid: 8544922
doi: 10.5588/ijtld.21.0515
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT05941052?term=NCT05941052&rank=1 (2023).
PAN-TB collaboration. Project to accelerate new treatments for tuberculosis (PAN-TB). PAN-TB https://www.pan-tb.org/newsroom/ (2021).